Dr. Damon Tojjar

Education and training

M.D., Lund University. Medical training across internal medicine, surgery, psychiatry, and family medicine.

Ph.D. candidate, medical science. Doctoral research at the Lund University Diabetes Centre, on the genetics of type 2 diabetes.

Research Fellow, Systems Medicine, Stanford. Diabetes genetics and computational biology with Professor Atul Butte. Anna Lindh Fellow.

Training. FDA Clinical Investigator training; Medical Device Regulations training, KTH (EU MDR, IVDR, FDA, SaMD); Health Care Outcomes Management, Harvard T.H. Chan.

Selected experience

EASY Diabetes Co-developer and Head of Medical and Science. An AI-based clinical decision-support system for type 2 diabetes, developed with patients, clinicians, and researchers. Its randomized controlled trial, EASY-1 (NCT03258268), compared the system against standard of care. EASY Diabetes received the Medtech4Health Innovation Award.

Vi-Health Co-founder and Managing Director. A digital health company offering an AI symptom checker and e-consultation tools. Vi-Health was selected as one of 20 finalists (Top 20 Deep Tech) in the European Institute of Innovation and Technology's EIT Digital Challenge and was later acquired by Numan.

Novo Nordisk, Global Development International Medical Manager and Principal Medical Specialist. Helped lead global clinical programs for GLP-1, insulin, and combination therapies, including Tresiba, Ryzodeg, and Xultophy, keeping the clinical evidence solid while the work ran across many countries.

Selected publications (Tojjar, D.)

Science. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Tojjar, D. (shared / co-second author). Magnus Blix Award. doi.org/10.1126/science.1176827

Diabetes Care. Ethnic differences in the relationship between insulin sensitivity and insulin response. Tojjar, D. (co-author). Systematic review and meta-analysis. Widely cited. doi.org/10.2337/dc12-1235

Diabetologia. Polymorphisms in the Ca2+ channel CaV2.3 (CACNA1E) and type 2 diabetes. Tojjar, D. (co-author). Gene discovery and impaired insulin secretion. doi.org/10.1007/s00125-007-0846-2

Diabetes, Obesity and Metabolism. Comparison of insulin degludec with insulin detemir in type 1 diabetes. Tojjar, D. (co-author). One-year treat-to-target trial. doi.org/10.1111/dom.12573

Awards and recognition

Awards: Magnus Blix Award, for the Science publication, Medtech4Health Innovation Award, for EASY Diabetes, EIT Digital Challenge Top 20 Deep Tech finalist, for Vi-Health.

Fellowships and training: Research Fellow in Systems Medicine, Stanford, Anna Lindh Fellow, Stanford, Harvard T.H. Chan health-outcomes course, FDA Clinical Investigator training, Medical Device Regulations training, KTH.

Board, advisory and mentorship: Nucleate biotech mentor, Mentor, UCLA Ventures, Board member, LU Innovation (now LU Ventures) and LU Holding, Lund University, Council member, Swedish Association of Family Medicine (quality and patient safety), Grant reviewer, Pivotal Philanthropies Action for Women's Health, Selected participant, Prince Daniel's Fellowship program (IVA).

Languages

Swedish, English and Persian (all native); Danish, Norwegian (working understanding); Italian (partial).